MENU

Whole-Brain Radiotherapy Shows No Survival Benefit over Targeted Radiotherapy for Patients with Limited Brain Tumor Metastases

September 26, 2016

PHILADELPHIA (September 26, 2016) – Whole-brain radiation appears to confer no obvious survival advantage when compared with more targeted radiation for patients whose cancer has metastasized to limited areas of the brain but who otherwise have controlled extracranial disease or a favorable predicted prognosis.

Thomas M. Churilla, MD, a resident physician at Fox Chase Cancer Center, presented the results of a secondary analysis of a prospective randomized trial at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting. Stephanie Weiss, MD, Chief of Neurologic Oncology at Fox Chase, and Brian Alexander, MD, Disease Center Leader, Radiation Oncology, Center for Neuro-Oncology, Dana-Farber Cancer Institute, were senior authors on the study.

Historically, whole-brain radiation therapy (WBRT) has been the standard of care when cancer spreads to the brain. However, because of the short- and long-term side effects of WBRT, including permanent cognitive decline, investigators increasingly offer focal therapies, such as stereotactic radiosurgery (SRS), which focuses  high-dose of radiation directly to tumors, sparing normal brain tissue, in lieu of WBRT.

Four gold-standard studies have shown that while the addition of WBRT to SRS for patients with four or fewer brain metastases (or oligometastatseis) helps prevent relapse in the brain, this advantage does not translate to a survival benefit. Investigators have speculated that this finding is due to either cancer outside the brain typically remaining the bigger threat to most patients or salvage treatment options being effective, or both.  

To address this question, Fox Chase researchers used the largest of the data-sets to examine the effect of WBRT on patient survival while extracranial disease remained under control. Therefore, only patients at high risk of death from brain metastases were analyzed because the main competing risk of extracranial progression was removed from the equation, according to Churilla. Additionally, to determine if those who might benefit from WBRT could be identified at diagnosis, the researchers evaluated the impact of WBRT on survival in patients with a favorable calculated prognosis.

Results showed that patients who continued to have controlled extracranial disease after receipt of WBRT tended to have a slightly longer survival than those who did not receive WBRT, but the researchers concluded that the possibility it was a chance finding could not be discounted. Given the known side effects of WBRT, Churilla and colleagues concluded that their “analysis supports the use of stereotactic radiosurgery alone for patients with limited brain disease undergoing close, active surveillance.”

“Because this is a secondary analysis, the study design and statistical power limit us from definitive conclusions,” Weiss said. “But in this data set, we were unable to detect a subgroup of patients who received a survival benefit from the improved brain control offered by the addition of whole-brain radiation to targeted therapy. Further work will likely continue to examine the benefits of differing radiotherapeutic strategies and targeted drugs based on the molecular and genetic profiles of a given tumor.”

       

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. 
For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Connect with Fox Chase